AbbVie, Inc. (ABBV Quick QuoteABBV ) announced that it has submitted a regulatory application in the United States, seeking approval for its interleukin-23 (“IL-23”) inhibitor Skyrizi (risankizumab) as a potential treatment for moderate to severe Crohn’s disease (“CD”).
The regulatory filing seeks approval for Skyrizi both as a 600mg intravenous (“IV”) induction and 360mg subcutaneous (“SC”) maintenance therapy in patients aged 16 years and older with CD.
The filing is supported by data from three phase III studies —....More>>>
